Kausik Umanath

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9067447/publications.pdf

Version: 2024-02-01

30 papers	1,388 citations	686830 13 h-index	525886 27 g-index
31 all docs	31 docs citations	31 times ranked	1667 citing authors

#	Article	IF	Citations
1	Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience. Journal of Cardiac Failure, 2022, 28, 21-31.	0.7	8
2	High SARS-CoV-2 Viral Load in Urine Sediment Correlates with Acute Kidney Injury and Poor COVID-19 Outcome. Journal of the American Society of Nephrology: JASN, 2021, 32, 2517-2528.	3.0	30
3	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International, 2021, 100, 215-224.	2.6	182
4	Pharmacological Effects of Exâ€‰Vivo Mesenchymal Stem Cell Immunotherapy in Patients with Acute Kidney Injury and Underlying Systemic Inflammation. Stem Cells Translational Medicine, 2021, 10, 1588-1601.	1.6	9
5	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 2020, 35, 1700-1711.	0.4	107
6	Hypertension: A Common but Complex Condition. Advances in Chronic Kidney Disease, 2019, 26, 85-86.	0.6	1
7	Update on Diabetic Nephropathy: Core Curriculum 2018. American Journal of Kidney Diseases, 2018, 71, 884-895.	2.1	550
8	Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). American Journal of Kidney Diseases, 2018, 71, 352-361.	2.1	104
9	Diabetic Kidney Disease: The Tiger May Have New Stripes. American Journal of Kidney Diseases, 2018, 72, 631-633.	2.1	9
10	Getting to the Heart of the Matter: Review of Treatment of Cardiorenal Syndrome. Advances in Chronic Kidney Disease, 2017, 24, 261-266.	0.6	4
11	Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis. Hemodialysis International, 2017, 21, 243-249.	0.4	4
12	The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis. Clinical Nephrology, 2017, 87, 124-133.	0.4	6
13	Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. Journal of the American Society of Hypertension, 2016, 10, 847-856.	2.3	56
14	Health care providersâ€™ support of patientsâ€™ autonomy, phosphate medication adherence, race and gender in end stage renal disease. Journal of Behavioral Medicine, 2016, 39, 1104-1114.	1.1	12
15	FP590FERRIC CITRATE (FC) AS A PHOSPHATE BINDER IN PERITONEAL DIALYSIS (PD). Nephrology Dialysis Transplantation, 2015, 30, iii270-iii270.	0.4	0
16	The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. American Journal of Kidney Diseases, 2015, 66, 479-488.	2.1	41
17	Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. Journal of the American Society of Nephrology: JASN, 2015, 26, 2578-2587.	3.0	88
18	Self-Motivation Is Associated With Phosphorus Control in End-Stage Renal Disease. , 2015, 25, 433-439.		21

#	Article	IF	Citations
19	Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 74 (Irbesartan Diabetic Nephropathy Trial). American Journal of Kidney Diseases, 2015, 66, 450-458.	2.1	37
20	Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data. Drugs in R and D, 2015, 15, 271-279.	1.1	12
21	Pyridoxamine Dihydrochloride in Diabetic Nephropathy (PIONEER-CSG-17): Lessons Learned from a Pilot Study. Nephron, 2015, 129, 22-28.	0.9	30
22	Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials. Clinical Investigation, 2015, 5, 551-559.	0.0	0
23	Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 545-550.	0.7	22
24	Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data. Expert Review of Clinical Pharmacology, 2014, 7, 705-710.	1.3	2
25	Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy. CKJ: Clinical Kidney Journal, 2014, 7, 53-56.	1.4	18
26	Guidelines and Straitjackets: Blood Pressure Targets in the Era of theÂEighth Joint National Committee. American Journal of Kidney Diseases, 2014, 63, 895-899.	2.1	2
27	Optimizing Blood Pressure Control in Patients With Nondiabetic Glomerular Disease. Advances in Chronic Kidney Disease, 2014, 21, 200-204.	0.6	4
28	Rationale and study design of a threeâ€period, 58â€week trial of ferric citrate as a phosphate binder in patients with <scp>ESRD</scp> on dialysis. Hemodialysis International, 2013, 17, 67-74.	0.4	20
29	Ferric citrate: a novel phosphate-binding agent. Expert Review of Endocrinology and Metabolism, 2013, 8, 13-19.	1.2	5
30	Inâ€Center Thrombolysis for Clotted AV Access: A Cohort Review. Seminars in Dialysis, 2013, 26, 124-129.	0.7	4